



Windlas Biotech Limited

Reg. Off.: 40/1, Mohabewala Industrial Area  
Dehradun, Uttarakhand 248 110, India  
Tel.:+91-135-6608000-30, Fax:+91-135-6608199

Corp. Off.: 705-706, Vatika Professional Point, Sector-66,  
Golf Course Ext. Road, Gurgaon, Haryana 122 001, India  
Tel.:+91-124-2821030

CIN-U74899UR2001PLC033407

Ref No. WBL/SE/2021-2022

December 21, 2021

To  
Listing / Compliance Department  
BSE Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street, Mumbai – 400 001

To  
Listing / Compliance Department  
National Stock Exchange of India Limited  
Exchange Plaza, C-1, Block G  
Bandra Kurla Complex  
Bandra (E), Mumbai – 400 051

**BSE CODE: 543329**

**NSE SYMBOL: WINDLAS**

Dear Sir/ Madam.

**Sub: Press Release**

Please find attached herewith press release dated December 21, 2021, regarding appointment of Chief Business Officer (CBO) by the Company.

Kindly take the same on record.

Thanking you,

Yours faithfully,

**For Windlas Biotech Limited**

Ananta Narayan Panda  
**Company Secretary & Compliance Officer**



**Press Release****Windlas Biotech Limited Strengthens Senior Management Capability*****Appoints Mr. Shailendra Rastogi as Chief Business Officer (CBO)***

**Tuesday, 21<sup>st</sup> December 2021, Gurugram:** Windlas Biotech Limited, one of the top five players in the domestic pharmaceutical formulations contract development and manufacturing organization (“CDMO”) industry in India has further strengthened the senior management capability with appointment of Mr. Shailendra Rastogi as a Chief Business Officer. He would be responsible for handling CDMO, Export, API & CRAMS business development for the company.

**Brief Profile**

- 22+ years of experience in Pharmaceutical Sales & Business Development.
- MBA- Marketing from CSJM University, Kanpur, MSc - Chemistry from Lucknow University & Bachelor of Science from Lucknow University.
- Prior to joining Windlas Biotech Limited, he was associated with “Mehta API Private Ltd.”, as an Associate Vice President (AVP) - Business Development. Prior to that he was associated with GVK Biosciences Pvt. Limited, Ind Swift laboratories Ltd, Parabolic Drugs Ltd, Syngene International Ltd. (Biocon Ltd) , Alembic Ltd., Merck Ltd. & AIMIL Ltd at various capacities in sales and business development .

“With his rich experience and a long track record of working with leading Pharmaceutical companies, Shailendra brings in lots of expertise and fresh insights to the table. His appointment has further strengthened the senior management team and would further sharpen the focus on strategic business development. I congratulate him on his new role and look forward to working with him to achieve our long term vision and goals” said Mr. Hitesh Windlass, Managing Director – Windlas Biotech.

**About Windlas Biotech Limited**

The company (Windlas) is amongst the top five players in the domestic pharmaceutical formulations contract development and manufacturing organization (“CDMO”) industry in India in terms of revenue. With over two decades of experience in manufacturing both solid and liquid pharmaceutical dosage forms and significant experience in providing specialized capabilities, including, high potency, controlled substances and low solubility, the Company provides a comprehensive range of CDMO services ranging from product discovery, product development, licensing and commercial manufacturing of generic products, including complex generics, in compliance with current Good Manufacturing Practices (“GMP”) with a focus on improved safety, efficacy and cost.

**Safe Harbor**

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and

development, potential project characteristics, project potential and target dates for project-related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

**For more information please contact:**



**Windlas Biotech Limited**

CIN: U74899UR2001PLC033407

Ms. Komal Gupta

Email: [Komal@windlasbiotech.com](mailto:Komal@windlasbiotech.com)

Contact no.: +91 124 2821034



**Strategic Growth Advisors Pvt. Ltd.**

CIN: U74140MH2010PTC204285

Mr. Jigar Kavaia / Mr. Chinmay Madgulkar

Email: [jigar.kavaia@sgapl.net](mailto:jigar.kavaia@sgapl.net) / [chinmay.m@sgapl.net](mailto:chinmay.m@sgapl.net)

Contact no.: +91 9920602034 / +91 9860088296